Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oramed Pharmaceuticals (ORMP) Return on Equity (2022 - 2025)

Oramed Pharmaceuticals' Return on Equity history spans 4 years, with the latest figure at 0.63% for Q4 2025.

  • For Q4 2025, Return on Equity changed N/A year-over-year to 0.63%; the TTM value through Dec 2025 reached 0.63%, changed N/A, while the annual FY2023 figure was 0.03%, N/A changed from the prior year.
  • Return on Equity reached 0.63% in Q4 2025 per ORMP's latest filing, up from 0.19% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.63% in Q4 2025 to a low of 0.28% in Q4 2022.
  • Average Return on Equity over 4 years is 0.01%, with a median of 0.01% recorded in 2025.
  • Peak YoY movement for Return on Equity: rose 30bps in 2023, then dropped -17bps in 2025.
  • A 4-year view of Return on Equity shows it stood at 0.28% in 2022, then skyrocketed by 108bps to 0.02% in 2023, then increased by 18bps to 0.03% in 2024, then soared by 2284bps to 0.63% in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Return on Equity are 0.63% (Q4 2025), 0.19% (Q3 2025), and 0.03% (Q2 2025).